• Press Releases
  • News Articles
March 13, 2025

Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers

View Press Release
July 23, 2024

Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases

View Press Release
Third Arc Bio's multispecific antibodies in light and dark green and light and dark blue against a white background.
Abstract lime green geometric mesh pattern on a navy blue background.Abstract lime green geometric mesh pattern on a navy blue background.